A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types by Jamieson, Stephen et al.
Biochem. J. (2011) 438, 53–62 (Printed in Great Britain) doi:10.1042/BJ20110502 53
A drug targeting only p110α can block phosphoinositide 3-kinase signalling
and tumour growth in certain cell types
Stephen JAMIESON*†, Jack U. FLANAGAN*†, Sharada KOLEKAR‡, Christina BUCHANAN†‡, Jackie D. KENDALL*†,
Woo-Jeong LEE‡, Gordon W. REWCASTLE*†, William A. DENNY*†, Ripudaman SINGH*, James DICKSON§,
Bruce C. BAGULEY*† and Peter R. SHEPHERD†‡1
*Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1042, New Zealand, †Maurice Wilkins Centre
for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland, New Zealand, ‡Department of Molecular Medicine and Pathology, University of Auckland,
Medical School, Private Bag 92019, Auckland 1042, New Zealand, and §School of Biological Science, University of Auckland, Private Bag 92019, Auckland 1042, New Zealand
Genetic alterations in PI3K (phosphoinositide 3-kinase)
signalling are common in cancer and include deletions in PTEN
(phosphatase and tensin homologue deleted on chromosome 10),
ampliﬁcations of PIK3CA and mutations in two distinct regions
of the PIK3CA gene. This suggests drugs targeting PI3K, and
p110α in particular, might be useful in treating cancers. Broad-
spectrum inhibition of PI3K is effective in preventing growth
factor signalling and tumour growth, but suitable inhibitors of
p110α have not been available to study the effects of inhibiting
this isoform alone. In the present study we characterize a novel
small molecule, A66, showing the S-enantiomer to be a highly
speciﬁcandselectivep110α inhibitor.Usingmolecularmodelling
and biochemical studies, we explain the basis of this selectivity.
Usingapanelofisoform-selectiveinhibitors,weshowthatinsulin
signalling to Akt/PKB (protein kinase B) is attenuated by the
additive effects of inhibiting p110α/p110β/p110δ in all cell lines
tested. However, inhibition of p110α alone was sufﬁcient to
block insulin signalling to Akt/PKB in certain cell lines. The
responsive cell lines all harboured H1047R mutations in PIK3CA
and have high levels of p110α and class-Ia PI3K activity. This
may explain the increased sensitivity of these cells to p110α
inhibitors. We assessed the activation of Akt/PKB and tumour
growth in xenograft models and found that tumours derived from
two of the responsive cell lines were also responsive to A66 in
vivo. These results show that inhibition of p110α alone has the
potential to block growth factor signalling and reduce growth in
a subset of tumours.
Key words: p110α E545K mutation, pan-phosphoinositide 3-
kinase (PI3K)/mammalian target of rapamycin (mTOR) inhi-
bitor NVP-BEZ235; phosphoinositide 3-kinase α (PI3Kα), phos-
phoinositide 4-kinase (PI4K), PIK3CA, PIK3CA H1047R
mutation.
INTRODUCTION
The three class-Ia PI3Ks (phosphoinositide 3-kinases;
p110α/p110β/p110δ) and the sole class-Ib PI3K (p110γ) couple
growth factor receptors and G-protein-coupled receptors to a
wide range of downstream pathways [1–3]. These enzymes
have different tissue distributions, difference in methods of
activation and different kinetic properties [4–6], but they all
use PtdIns(4,5)P2 to produce PtdIns(3,4,5)P3. The cellular
levels of PtdIns(3,4,5)P3 are tightly controlled by phosphatases,
including PTEN (phosphatase and tensin homologue deleted on
chromosome 10) which dephosphorylates PtdIns(3,4,5)P3 back
to PtdIns(4,5)P2 [7,8]. The importance of this pathway in cancer
is highlighted by the fact that defects in both the kinase and
phosphatase activities are commonly observed in tumours. PTEN
is a tumour suppressor gene whose function is commonly lost
in tumours [7,8], whereas the PIK3CA gene, which codes for
p110α, appears to be the most important form of PI3K involved
in solid tumours as it is commonly mutated [9,10] or ampliﬁed
[11] in such cancers. The mutations in PIK3CA mainly occur in
two distinct regions of the gene. It is not fully understood how
these mutations contribute to the development of tumours, but
they do confer a modest increase in catalytic activity [12,13],
are capable of inducing transformation of cultured cells [14–16]
and are capable of inducing tumours in vivo [17,18]. However,
evidence is emerging that the main two different hot spot
mutations in PIK3CA represent functionally distinct oncogenic
activities [12,13,19–23]. The full implications of PIK3CA gene
ampliﬁcation are not fully understood, but presumably act by
increasing overall PI3K activity levels.
The identiﬁcation of oncogenic mutations and ampliﬁcations
in PIK3CA has spurred the development of a wide range of small-
molecule inhibitors targeting PI3K, with many of these currently
in clinical trials [2,24,25]. Most of the compounds developed
to date target multiple PI3K isoforms and related kinases such
as mTOR (mammalian target of rapamycin). Compounds in this
class show efﬁcacy in inhibiting growth of cells in culture and
xenograft models [2,24,25]. However, a question that remains
to be answered is whether selectively targeting p110α might
achievesimilarresultsgiventhatthisseemstobethepredominant
oncogenic form of class-I PI3Ks.
The potential importance of targeting p110α is shown by
studies showing speciﬁc genetic knockdown of PIK3CA does
block cell signalling and cell growth in a range of tumour lines
[26–28]. To date the lack of suitable small-molecule inhibitors
has meant that it has not been possible to properly evaluate
whether pharmacological inhibition of p110α can achieve similar
effects. Only one series of small molecules has been described
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that has a high degree of selectivity for p110α compared with
other PI3K isoforms [29]. One member of this family, PIK-75,
has been used to study the role of p110α, but was found to have
signiﬁcant off-target activity [30], meaning it is difﬁcult to know
whether any actions of this drug are in fact due to its activity
against PI3K. Despite these limitations, this drug has been used
in some studies to infer that blocking p110α is sufﬁcient to block
signalling to Akt/PKB (protein kinase B) in some cell types but
not others [28,31,32]. Furthermore, compounds related to
PIK-75haveshownantitumouractivityinvivo,hintingthatp110α
inhibitionmightbeausefultherapeuticstrategy[29,33].However
these ﬁndings cannot be conﬁrmed until a suitably clean p110α-
selective inhibitor is available.
In the present paper, we report the properties of A66, a
compound that was recently found to be a potent p110α inhibitor
[34]. We show that this compound is highly selective for p110α
over other PI3Ks and has a high degree of speciﬁcity as it does
not target other protein kinases tested. We use this to demonstrate
that inhibition of p110α attenuates signalling in a subset of cell
typesthatarecharacterizedbyhavingkinasedomainmutationsin
PIK3CA, high p110α levels and high total class-1a PI3K activity.
We go on to show that A66 has efﬁcacy in retarding growth
of tumours in in vivo xenograft models that use cell lines that
were responsive in culture. These results show that inhibition of
p110α alone has the potential to block growth factor signalling
and reduce growth in a subset of tumours.
MATERIALS AND METHODS
Inhbitors
The S-enantiomer of A66 (Figure 1) was prepared as described
in Patent WO 2009/080705 [35], except that 2-(tert-butyl)-
4
 -methyl-[4,5
 -bithiazol]-2
 -amine was converted into A66
in one-pot by addition of L-prolinamide directly to the
intermediate imidazolide solution. Aqueous work-up followed
by recrystallization from aqueous methanol gave A66 as a white
solid with a 81% yield.
1H NMR (400 MHz, CDCl3) δ 8.56
(br s, 1H), 7.03 (s, 1H), 6.76 (br s, 1H), 5.65 (br s, 1H), 4.62
(d, J 8.0 Hz, 1H), 3.62 (m, 1H), 3.49 (m, 1H), 2.52 (s, 3H),
2.43 (m, 1H), 2.03–2.20 (m, 3H), 1.45 (s, 9H). LC-MS (APCI
+)
394 (MH
+, 100%). Analysis calculated for C17H23N5O2S2:C ,
51.89; H, 5.89: N, 17.80. Found C, 51.85; H, 5.84; N, 17.81. The
R-enantiomer of A66 was synthesized in the same way, except
that D-prolinamide was used. Compound SN34452 was prepared
similarly using pyrrolidine.
1H NMR (400 MHz, CDCl3) δ 7.78
(br s, 1H), 7.02 (s, 1H), 3.48 (m, 4H), 2.54 (s, 3H), 2.00 (m, 4H),
1.45 (s, 9H). LC-MS (APCI
+) 351 (MH
+, 100%). Analysis
calculated for C16H22N4OS2: C, 54.83; H, 6.33; N, 15.98. Found
C, 55.10; H, 6.47; N, 15.94.
NVP-BEZ-235 was synthesized as described previously [31].
PIK-75, TGX-221 and IC87114 were obtained from Symansis.
LY294002 and wortmannin were obtained from Sigma–Aldrich.
Modelling
An energy-minimized model of A66 was generated using
SKETCHER (SYBYL8.2, Tripos) and minimized using
MAXMIN2withtheMMFF94sforceﬁeldandMMFF94charges.
Minimization was performed using 1000 steps of step descents
followed by conjugate gradients until convergence at the
0.05 kcal/(mol·A) level. A distance-dependent dielectric function
was used with a dielectric constant of 80. The major tautomer at
pH 7.4 was generated using ChemAxon software. Docking was
performedusingGOLDv5.0.Theapop110α structure(PDBcode
2RD0)waspreparedbystrippingallwatermoleculesandtheaddi-
Figure 1 Structure of A66 and its inactive analogue SN34452
tionofprotonsusingSYBYL8.2,andside-chainorientationswere
modiﬁedaccordingtotheresultsofMolProbity[36].Thedocking
site was deﬁned as an 18 Å (1 Å = 0.1 nm) cavity centred on the
Ile
800 CD1 atom. The Chemscore ﬁtness function with kinase
modiﬁcation was used as the scoring function and 20 Genetic
Algorithmrunswereperformedusingasearchefﬁciencyof200%
with all poses were kept. Atom types for both protein and ligand
were generated automatically and all ligand ﬂexibility terms were
turned on, although Ring-NH2 and Ring-NR1R2 were set to
ﬂip, other settings were kept at default. All docking poses were
minimized and rescored using the kinase-modiﬁed Chemscore
with receptor depth scaling implemented. X-ray crystal structures
forp110γ (PDBcode2CHZ)andp110δ (PDBcode2WXR)were
superimposedontop110α usingPyMOL(http://www.pymol.org)
and docking was performed under the same conditions with the
18 Å cavity centred on the CD1 of Ile
744 and Ile
777 respectively.
Assays
IC50 values were evaluated using the PI3K (human) HTRF Assay
(Millipore, #33-016). p85α/p110δ was obtained from Invitrogen.
All other isoforms were produced in-house by co-expressing
full-length human p85α with the indicated human full-length
catalytic subunit containing a histidine tag at the N-terminus
to allow puriﬁcation. The PI3Ks were titrated and used at a
concentration between their EC65–EC80 values. PI3K activity
in immunoprecipitates was assayed as described previously [5]
using an antibody to the N-SH2 (N-Src homology 2) domain
of p85α (Symansis). Assays for other lipid kinases and protein
kinaseswereperformedbytheNationalCentreforProteinKinase
Proﬁling(Dundee,U.K.)andInvitrogenDrugDiscoveryServices
(Madison, WI, U.S.A.).
Pharmacokinetic methods
All animal experiments followed protocols approved by the
Animal Ethics Committee of The University of Auckland.
Age-matched speciﬁc pathogen-free male CD-1 mice were
administered a single dose of A66 (10 mg/kg of body weight)
in 20% 2-hydroxypropyl-β-cyclodextrin in water or BEZ-235 in
15% (v/v) DMSO, 20% (v/v) 0.1 M HCl, 0.7% Tween 20 and
64.3% (v/v) saline. Mice were killed at ﬁve or six time points
after dosing (n=3/time point) and blood was removed by cardiac
puncture into EDTA collection tubes (Becton Dickinson). Blood
samples were centrifuged for 10 min at 6000 rev./min at 20◦C
and the plasma supernatant was retained. Methanol was added to
the plasma for protein extraction. Quantitative analysis was per-
formedonanAgilent6460triplequadrupoleLC-MS/MS(tandem
MS) (Agilent Technologies) using multiple reaction monitoring
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and electrospray ionization. For chromatographic separation, an
Agilent Zorbax SB-C18 column (2.1 mm×50 mm; 5 μm) was
used with a mobile phase gradient of 20–100% methanol in
0.1% formic acid and 5 mM ammonium formate at a ﬂow rate of
0.4 ml/min. Plasma drug concentrations were quantiﬁed against a
calibrationcurveofknowndrugconcentrationsrangingfrom10to
10000 nM,withqualitycontrolsincludedat65,650and6500 nM.
To prevent contamination from previous samples, a methanol
slug was run between each plasma sample. Pharmacokinetic
parametersweredeterminedbynoncompartmentalanalysisusing
WinNonlin 5.3 software (Pharsight).
Cell cultures and Western blotting
TreatmentofcellswithdrugsandWesternblottingwasperformed
as described previously [31]. All antibodies for Western
blotting were from Cell Signaling Technologies. Melanoma cell
cultures were established and genotyped in-house. Established
celllineswereobtainedfromA.T.C.C.andgenotypesforcelllines
were assigned on the basis of data from the COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/CellLines/).
Xenograft methods
Age-matched speciﬁc pathogen-free Rag1
−/− or NIH-III mice
were subcutaneously inoculated on the right ﬂank with 5×10
6
U87MG, SK-OV-3 or HCT-116 cells in PBS. Tumour diameter as
measured by electronic calipers was used to calculate tumour
volume (mm
3) based on the formula (L×w
2)×π/6 (where
L=longest tumour diameter and w = perpendicular diameter).
A66 was administered in 20% 2-hydroxypropyl-β-cyclodextrin
(Sigma–Aldrich) in water, whereas BEZ-235 was administered in
10% ethanol. Control mice were administered the A66 dosing
vehicle alone. The drugs were dosed by intraperitoneal injection
as the free base equivalent at a dosing volume of 10 ml/kg of
body weight. For tumour pharmacodynamic studies, mice were
administered a single dose of A66 or the control vehicle when
tumours reached approximately 8–9 mm in diameter. Animals
were killed 1 or 6 h after dosing and the tumours were removed,
biopulverized and assayed for protein concentration (BCA
protein assay; Sigma–Aldrich). For antitumour efﬁcacy studies,
dosing began when tumours were well established, averaging
approximately 7 mm in diameter. Doses were administered once
daily (QD) or twice daily (BID) with injections separated by
a minimum of approximately 8 h. Different dosing schedules
were used for the three xenograft models depending on the
rate of tumour growth and the body weight tolerance of control
mice. Animals were dosed daily for 21 days or twice daily for
16 days (SK-OV-3), daily for 14 days (U87MG) and daily for
7 days (HCT-116). Animals were monitored daily for any signs
of emerging toxicity and body weight was recorded. Mice were
killed if they developed moderate signs of toxicity or if body
weight loss exceeded 20% of starting weight. TGI (tumour
growth inhibition) was calculated on the ﬁnal day of dosing by
determining the relative tumour size of drug-treated mice as a
percentage of the average relative tumour size of control mice.
The statistical signiﬁcance of TGI values was determined by one-
wayANOVAwithBonferronimultiplecomparisonanalysisusing
GraphPad Prism 5.02.
RESULTS
Inhibitor speciﬁcity
WeﬁrstcharacterizedA66andconﬁrmeditwasapotentinhibitor
ofthewild-typeandoncogenicformsofp110α butnototherclass-
Table1 IC50 forindicateddrugsagainstdifferentPI3KisoformsusingHTRF
assay
IC50 values are in nM. ND, not determined.
PI3K isoform A66 S A66 R SN34452 PIK-75 TGX-221 IC87114
p110α 32 >5000 1560 6 >1000 >1000
p110α E545K 30 ND 540 24 >1000 >1000
p110α H1047R 43 ND 550 4.7 >1000 >1000
p110β> 12500 >12500 >25000 80 12 >1250
p110δ> 1250 >12500 >1000 164 130 41
p110γ 3480 ND 4350 33 >1250 >1250
Table 2 IC50 against PI3K-related kinases of A66 S form with or without the
carboximide group
IC50 values are in nM. ND, not determined.
Kinase A66 S SN34452
PI3K-C2α> 5000 >10000
PI3K-C2β 462 6500
PI3K class-III >5000 ND
mTOR >5000 ND
DNA-PK >5000 ND
PI4K α> 5000 >10000
PI4Kβ 236 478
I PI3K isoforms (Table 1). We found A66 has a much greater
degree of selectivity for p110α than PIK-75. Given the important
roles of class-II PI3Ks [37], class-III PI3K [38] and PI4Ks
(phosphoinositide 4-kinases) [39] in growth factor signalling, we
also assessed the activity of A66 towards these and found some
limited cross-reactivity with the class-II PI3K PI3K-C2β and the
PI4Kβ isoformofPI4K(Table2).Therewasnoinhibitionofother
lipidkinasesortherelatedkinasesDNA-PKandmTOR(Table2).
We also tested the inhibitory effects of 10 μM A66 effects on
two large panels of 110 protein kinases (Supplementary Figure
S1 at http://www.BiochemJ.org/bj/438/bj4380053add.htm) and
318 kinases (Supplementary Figure S2 at http://www.
BiochemJ.org/bj/438/bj4380053add.htm). These show A66 is
a very speciﬁc inhibitor of p110α, whereas PIK-75, the
compound described previously as a p110α-selective inhibitor,
inhibited a large number of protein kinases at this concentration
(Supplementary Figure S1). Our data for TGX-221 and IC87114
generated using the HTRF assay agreed with previous studies
using other assay methods and conﬁrmed these are highly
selective inhibitors of p110β and p110δ respectively (Table 1),
although TGX-221 will cross-react with p110δ at higher
concentrations [30,31,40]. We report further that these inhibitors
do not have any major effects on a panel of 110 protein kinases
(Supplementary Fig 1).
A66 shares its central aminothiazole scaffold with the known
PI3K inhibitor PIK-93, and the X-ray crystal structure of PIK-93
bound to the related p110γ isoform (PDB code 2CHZ) shows
that the embedded hydrogen-bond donor acceptor group in this
core interacts with the kinase domain through backbone amide
and carbonyl groups of the inter-lobe linker region amino acid
Val
882 [30]. The aminothiazole unit in A66 may also inﬂuence
its interaction with p110α by binding similarly, this is in part
supported by the inhibition of PI4K by both these compounds
[41]. The availability of the p110α X-ray crystal structure [42]
allowed modelling of A66 in the p110α kinase domain and
the likely mechanisms for its selectivity towards this compound
were identiﬁed. The top-ranked binding mode for the A66
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Figure 2 Model of A66 S form in binding pocket of p110α
S form docked into the p110α ATP-binding site (PDB code
2RD0),afterminimizationandrescoringwiththekinasemodiﬁed
Chemscore scoring function using receptor depth scaling, is
shown in Figure 2. Critically in this predicted binding mode,
the ligand forms an interaction with Val
851 of the inter-lobe
linker region. Both the backbone amide and carbonyl of Val
851
interact with the hydrogen bond donor and acceptor nitrogen
atoms embedded in the central aminothiazole core, consistent
with the binding mode observed for PIK-93 bound to p110γ
[30]. The tertiary butyl-thiazole moiety extends from the amino-
thioazole core into the lipophilic afﬁnity pocket, whereas the
pyrrolidine carboxamide group extends in the opposite direction
towards a region of the binding site wall deﬁned by the
C-terminal lobe that contains p110α-speciﬁc residues, known to
affect ligand binding [43]. In this predicted binding pose, the car-
boxamide amine moiety forms hydrogen bonds with the side-
chain carbonyl group of Gln
859 and possibly the backbone
carbonyl group of Ser
854 (Figure 2). Notably, the unminimized
pose predicted a hydrogen bond interaction between both the
carboxamide amide and carbonyl groups of the ligand and those
in the Gln
859 side chain. These residues were predicted previously
to be involved in inhibitor interactions in the p110α active
site [44].
We also investigated possible binding modes for the A66 R
form, and observed that a pose similar to that of the S form
was not found, and it failed to form a hydrogen bond interaction
with the backbone amide of Val
851 as well. In the top ranked
pose, the R pyrrolidine carboxamide amino group was predicted
to form a hydrogen bond with the Val
851 backbone carbonyl. In
this orientation, the ligand’s central urea carbonyl was predicted
to interact with the side-chain amino group of Gln
859 and also
the afﬁnity pocket was not occupied. Interestingly, a few clashes
between the protein and ligand were observed with the S form,
whereas more were present for that of the R form. These results,
taken together along with the higher Chemscore ﬁtness value (S,
17.46 compared with R, 13.26), indicate that the A66 S form
appears to complement better the p110α active site. In agreement
with this, we ﬁnd that the A66 R form lost inhibitory activity and
did not inhibit p110α at 10 μM( T a b l e1 ) .
Superimposition of the p110γ and p110δ kinase domains on to
that of p110α illustrates that in p110γ Lys
890 replaces the p110α
Gln
859, whereas in p110δ Asn
836 is the equivalent residue. As
both these amino acid side-chains have hydrogen bond donor and
acceptor groups that may interact with the ligand’s pyrrolidine
carboxamide, A66 was docked into the p110γ structure with the
aminothiazole containing PIK-93 bound (PDB code 2CHZ) and
the p110δ apo enzyme structure (PDB code 2WXR). The top
ranked pose predicted for A66 binding to p110γ had a similar
orientationtothatpredictedwithp110α;however,theChemscore
ﬁtness value was much lower, indicating a worse ﬁt (Chemscore
7.29 compared with 17.46). An interaction with the p110γ Val
882
backbone amide (the equivalent residue to p110α Val
851)w a s
also not predicted, even though the PIK-93 aminothiazole forms
this interaction. No interaction was observed with Lys
890 and,
moreover, the pyrrolidine group clashed with Trp
812 on the N-
terminal lobe wall of the active site, further supporting poor
complementarityofthiscompoundwithp110γ.AlowChemscore
value was also recorded for the top ranked pose in the p110δ
activesite(8.44comparedwith17.46),indicatingapoorﬁtinthis
isoform. In the present study, no pose was found that was similar
to those predicted in either the p110α apo structure or p110γ
PIK93structure,andaninteractionwiththebackboneamideofthe
p110α Val
851 equivalent, Val
828, was not observed. Neither was an
interactionwithAsn
836.Thelackofsimilaritybetweenthebinding
modepredictedforp110α andthoseforp110γ andp110δ suggest
that other active site features, more than residue substitutions at
Gln
859, may inﬂuence A66 binding. On the basis of the preferred
binding model of A66 in p110α, we characterized the role of the
carboxamide by docking an unsubstituted pyrrolidine derivative
SN34552(Figure1).ThebindingmodewassimilartothatofA66,
although the Chemscore was much lower in the absence of the
predictedcarboxamide-mediatedhydrogenbonds(8.44compared
with 17.46), suggesting reduced potency. This was supported by
biochemical data which showed that SN34452 has a much lower
potency against p110α (Table 1) and clearly indicates that the
pyrrolindine carboxamide group makes p110α-speciﬁc contacts
that are accessible in both the wild-type and oncogenic forms.
Interestingly, SN34452 largely retains its potency against PI4K
TypeIIIβ (Table2),whichindicatesthecarboxamideisnotcritical
for binding to this enzyme.
Effects of speciﬁcally inhibiting p110α on cell function
To investigate the role of p110α in regulating proximal elements
of PI3K-dependent signalling pathways, we determined the
ability of various concentrations of the A66 S form to acutely
block the activation of Akt/PKB in a range of cell lines
as assessed by both phosphorylation of Ser
473 and Thr
308
(Figure 3). Loading was controlled for by reprobing for total
PKB (see Supplementary Figure S3 at http://www.BiochemJ.
org/bj/438/bj4380053add.htm). We found that phosphorylation
of both Ser
473 and Thr
308 is sensitive to LY294002 in all cell lines
tested,implyingthatclass-IPI3Kactivityisrequiredforactivation
of Akt/PKB. However, we found the amount of the A66 S form
required to inhibit phosphorylation of Ser
473 and Thr
308 followed
two distinct patterns, being either sensitive to inhibition by the
A66 S form at concentrations consistent with it acting through
p110α orbeingresistant.Themostobviousfeatureofthesensitive
cell lines was that they harboured H1047R mutations in PIK3CA,
whereas all other cell lines were resistant. As a control we tested
the effect of the A66 R form and found it was not able to inhibit
the phosphorylation of Akt/PKB (see Supplementary Figure S4
at http://www.BiochemJ.org/bj/438/bj4380053add.htm).
We then went on to investigate this in more detail in a
larger panel of cell lines. The broader panel included early
passage melanoma cultures that were genotyped in-house (NZM
lines) [45]. The latter are likely to have characteristics more
representative of real tumour tissue. In these studies we used
PIK-75 as an alternative p110α inhibitor and we found that a
low concentration of PIK-75 also blocks the insulin-stimulated
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Figure 3 Effect of A66 S form on activation of Akt/PKB in cell lines
The indicated cell lines were serum-starved overnight and then treated with the indicated concentration of drug or DMSO vehicle for 15min prior to stimulation with 500nM insulin for 5min. Cells
were lysed and then analysed by Western blotting with the indicated antibody. Ly, LY294002.
phosphorylation of Thr
308 and Ser
473 on Akt/PKB in all lines
harbouring PIK3CA H1047R mutations (Figure 4A). TGX-221
and IC87114 had no effect in these cells.
PIK-75 was less effective in cell lines that lack the H1047R
mutation (Figure 4B), with the main exception being MCF7 cells,
where both PIK-75 and TGX-221 had a partial inhibitory effect.
In other cells, the activation of Akt/PKB was not inhibited by
TGX-221 or IC87114 at concentrations at which they would be
speciﬁcally inhibiting p110β or p110δ respectively. However, in
these cells, the combination of PIK-75, TGX-221 and IC87114
together did block activation of Akt/PKB, which was consistent
with the ﬁnding that wortmannin and LY294002 were also
effective.
To further understand why certain cell lines are sensitive to
p110α inhibitors, we compared total levels of class-Ia PI3K
activity in the eight cell lines used in Figure 3. The cell lines
that were responsive to the p110α inhibitors have signiﬁcantly
higher total levels of PI3K (Figures 5A and 5B). We next com-
pared total levels of p110α and p110β protein in the cell lines
used (Figure 5C). The levels of p110α were highest in the cell
lines that were responsive to A66 and PIK-75. These cells also
hadlevelsofp110β thatwerehigherthantheothercelllines,with
the exception of MCF7 cells which also had high levels of p110β.
It is of note that the MCF7 cells were the only cell line that had
a partial response to TGX-221 (Figure 4B) and this may relate to
the ratio of p110β/p110α in these cells.
Demonstrating A66 is effective in vivo
ToinvestigatewhethertheinhibitoryeffectsofA66Sonactivation
of Akt/PKB signalling translated into the ability to block cell
growth in vivo, we performed xenograft studies alongside the
well-established pan-PI3K inhibitor BEZ-235 in U87MG cells,
which are PTEN-null, and HCT-116 and SK-OV-3 cells, both
of which contain H1047R mutations. First, we determined the
optimal dosing strategy for xenograft studies by investigating
thedrugpharmacokineticsafteradoseof10 mg/kgofbodyweight
byintraperitonealinjectioninCD-1mice.Despiteashorthalf-life
ofonly0.42 h,thelargeCmax (8247 nM)ofA66Sthatwasreached
30 minafterdosingensuredthattheAUC0-inf (areaunderthecurve
fromzerotimetoinﬁnity)(6809 nM·h)wassimilartothatofBEZ-
235 (7333 nM·h), which has a longer half-life of 2.73 h (Table 3).
Furthermore, we tested the effect of the A66 S form on SK-OV-3
tumour tissue in vivo using a single dose of 100 mg/kg of body
weight to determine whether a long-lasting effect of the drug
could be achieved on target tissues (Figure 6). These studies show
that A66 S causes a profound reduction in the phosphorylation of
Akt/PKBandp70S6kinase,butnotofERK(extracellular-signal-
regulated kinase), at both 1 and 6 h after dosing (Figure 6). This
is consistent with A66 S having a full inhibitory effect on PI3K
signalling in the tumours during this time. In the present study,
levels of A66 S in plasma were determined to be 21.1+ −1.2 μM
and 9.1+ −1.1 μM at 1 and 6 h after drug injection, whereas levels
of A66 S in the tumour were 22.7+ −2.1 μM and 16.0+ −1.3 μM
at the same time points. Thus, the retention of drug in the tumour
is likely to explain the persistence of the inhibitory effect.
On the basis of the pharmacokinetic and pharmacodynamic
ﬁndings, A66 S was dosed QD at 100 mg/kg of body weight for
up to 21 days or BID at 75 mg/kg of body weight for 16 days
in tumour efﬁcacy studies. Both dosing strategies induced a
signiﬁcant delay in growth of SK-OV-3 xenografted tumours,
which was even greater than that induced by the well-established
pan-PI3K inhibitor BEZ-235 (Figure 7A). At the ﬁnal day
of dosing, the average TGI for A66 S form was 45.9% of
control (QD; P<0.05) and 29.9% of control (BID; P<0.01)
(Table 4). QD A66 S was well tolerated in this xenograft model
with minimum body weight loss; however BID treatment was
associated with moderate body weight loss and two deaths,
although it is not clear whether the deaths were due to drug
toxicity or other causes since these mice did not show signiﬁcant
body weight loss (Figure 7B). In comparison, BEZ-235 induced
a non-signiﬁcant reduction in tumour growth and was even
less tolerated, with moderate body weight loss and four deaths.
QD dosing of A66 S in an HCT-116 xenograft model also
induced a signiﬁcant reduction in tumour volume with a TGI
of 77.2% of control (P<0.01) at the end of dosing, but
caused a non-signiﬁcant reduction in tumour volume in the
U87MG xenograft model (Table 4 and Supplementary Figure S5
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Figure 4 Effect of isoform-selective inhibitors of PI3K on activation of Akt/PKB
TheindicatedcelllinesharbouringH1047Rmutations(A)orharbouringothermutations(B),wereserum-starvedovernightandthentreatedwiththeindicatedconcentrationofdrugorDMSOvehicle
for 15 min prior to stimulation with 500nM insulin for 5 min. Cells were lysed and then separated by SDS/PAGE using 20μg of protein per lane for all cell types, except T47D, SK-OV-3 and MCF7.
Western blots were performed with the antibodies indicated. LY, LY294002; PIK, PIK-75.
Figure 5 Levels of PI3K activity in different cell lines
(A) Toassesstherelative levels ofPI3Kactivity in differentcell lines,PI3K activity wasmeasuredin p85immunoprecipitatesfrom equivalentamountsofcell lysate. Results for the indicated celllines
were normalized to those for PC3 cells and are shown as means+ −S.E.M. (n = 4 for each). (B) The combined results for all cells of the same genotype. Statistical analysis was performed using
grouped ANOVA (*P <0.05, ***P <0.005). (C) Equal amounts of the indicated cell lysates were analysed by Western blotting for p110α, p110β and PTEN and reprobed to test for even loading
with β-actin.
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Figure 6 Effect of A66 S form on PI3K signalling in SK-OV-3 tumours
Western blotting was used to determine the phosphorylation status of Akt/PKB, p70 S6 kinase (pS6RbP) and ERK in SK-OV-3 tumours from mice 1 and 6 h after a single dose of A66 (100mg/kg of
body weight) or the control vehicle (n = 5).
Table 3 Plasma pharmacokinetic properties of A66 S form and BEZ-235 in
mice after a single intraperitoneal dose of 10 mg/kg of body weight
Drug Cmax (nM) Tmax (h) AUCo-inf (nM·h) T1/2 (h)
A66 8247 0.5 6809 0.42
BEZ-235 1863 0.25 7333 2.73
at http://www.BiochemJ.org/bj/438/bj4380053add.htm). In con-
trast,BEZ-235signiﬁcantlyreducedU87MGtumourgrowth(TGI
= 61.1% of control; P<0.05), but had no effect on HCT-116
tumours. The drugs were well tolerated in both the U87MG
model, despite the toxicity with the same dose level of BEZ-
235 in the SK-OV-3 study, and in the HCT-116 model, where a
lower dose (10 mg/kg of body weight) of BEZ-235 was used due
to the moderate body weight loss of control-treated mice.
DISCUSSION
The present study demonstrates that A66 S is a highly speciﬁc
and selective inhibitor of p110α that is suitable for in vitro and
in vivo studies. The contacts made by the carboxamide group give
A66 S its potency and selectivity for p110α but, interestingly,
it does inhibit PI4K IIIβ at concentrations approximately one
order of magnitude higher. This is not surprising given the degree
of homology between these enzymes in the catalytic sites [41].
However, SN34452 retains this activity against PI4K IIIβ when
the carboxamide is removed (Table 2), which makes this one
o ft h em o r es e l e c t i v eP I 4 KI I I β inhibitors described to date [41].
The other is PIK-93, which is structurally quite different from
A66 apart from sharing an amino thiazole core, but it also inhibits
both p110α and PI4K IIIβ, again highlighting the similarities in
the catalytic site of these two enzymes [41].
Our results conﬁrm previous studies that highlight the
limitations of using PIK-75 and related compounds [30].
However, PIK-75 can still play a useful role as a backup for
conﬁrmatory experiments and it is worth noting that PIK-75
complements A66 in that it does not inhibit the two non-p110α
lipid kinases that A66 targets, i.e. PI4K IIIβ and PI3K-C2β.
Our studies also add extra weight to the case for TGX-221 and
IC87114 being considered as highly selective inhibitors of p110β
and p110δ if used at suitable concentrations.
Figure 7 In vivo antitumour efﬁcacy and body weight change following
treatment with A66 S form and BEZ-235 in a SK-OV-3 tumour xenograft
model
A66 was administered QD×21 at 100mg/kg of body weight or BID until day 16 at 75mg/kg
of body weight, and BEZ-235 was administered QD×21 at 15 mg/kg of body weight. (A)
Relative mean tumour volume following treatment with A66 and BEZ-235. Using one-way
ANOVA analysis, the signiﬁcance of tumour shrinkage compared with controls was calculated
at days 8,12, 16 and 20 and found to be signiﬁcantly different in the following conditions; BID
A66day 8 (P <0.05), BID A66day 12 (P <0.005), BID A66 day 12 (P <0.005), BID A66day
16 (P <0.005), BID A66day 20 (P <0.01), QD A66day 16 (P <0.05) and QD A66day 20
(P <0.05). (B) Bod yweight change from start of treatment in mice treated with A66 and
BEZ-235. Values are means+ −S.E.M. for seven or eight mice per group.
The ﬁnding that A66 S potently blocks phosphorylation of
Akt/PKB in a subgroup of the cell lines tested demonstrates that
some cell types are highly dependent on p110α activity. This is
consistent with genetic studies which show that knockdown of
p110α blocked signalling to Akt/PKB in cell lines harbouring
mutations in PI3K [26,27]. It also supports previous studies using
PIK-75 [28,31,33] and A66 [34] and suggests at least some cell
types are more sensitive to p110α inhibitors. The ﬁnding that
TGX-221 and IC87114 alone do not inhibit the phosphorylation
of Akt/PKB at Ser
473 or Thr
308 in any of the cell lines tested,
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Table 4 Summary of TGI and toxicity parameters for BEZ-235 and A66 S form in the SK-OV-3, HCT-116 and U87MG xenograft models
BWL, body weight loss; NS, not signiﬁcant.
Xenagraft model Control BEZ-235 A66
SK-OV-3 Dose (mg/kg of body weight) – 15 100
Schedule QD×21 QD×21 QD×21
BWL nadir (%) −2.0+ −1.9 −9.5+ −6.6 −4.3+ −2.2
Number of deaths/n 0/7 4/7 0/7
TGI(%) (day 20) – 69.4+ −6.4 45.9+ −4.6
P value NS <0.05
HCT-116 Dose (mg/kg of body weight) – 10 100
Schedule QD×7Q D ×7Q D ×7
BWL nadir (%) −6.7+ −2.9 −5.9+ −1.8 −6.0+ −2.0
Number of deaths/n 0/7 0/7 0/7
TGI(%) (day 7) – 117.7+ −6.6 77.2+ −2.7
P value NS <0.01
U87MG Dose (mg/kg of body weight) – 15 100
Schedule QD×14 QD×14 QD×14
BWL nadir (%) −5.5+ −3.0 −8.4+ −5.4 −8.7+ −3.1
Number of deaths/n 0/7 0/5 0/5
TGI(%) (day 11) – 61.1+ −8.1 78.0+ −9.4
P value <0.05 NS
with the exception of a partial effect of TGX-221 in MCF7 cells,
indicates that this pathway is not reliant on the catalytic activities
of p110β and p110δ in most cells. The ﬁndings with regard
to p110δ are not unexpected, but the ﬁndings with TGX-221
are somewhat at odds with some previous studies. Although no
oncogenicmutationshavebeenfoundinp110β,overexpressionof
p110β is capable of inducing transformation [46]. Knockdown
ofPIK3CBhasbeenshowntoblocktheabilityofPTEN-deﬁcient
cell lines to form foci in in vitro transformation assays [26,47,48]
and in in vivo tumour models. The knockdown of PIK3CB has
also been reported to result in a small reduction in Akt/PKB
phosphorylation in PTEN-deﬁcient cells [26,47,48]. Although
some functions of p110β appear to be independent of its lipid
kinaseactivity[49],theﬁndingthatTGX-221blockssignallingto
Akt/PKB in PTEN-deﬁcient cells has been taken as evidence that
the catalytic activity of p110β is required in this context [47,50].
However, it should be pointed out that those studies used a 20- to
100-fold higher concentration of TGX-221 than those used in the
present study, which would provide for a signiﬁcant opportunity
for cross-reactivity with other PI3K isoforms. In support of this,
Wee et al. [26] found that 2 μM TGX-221 was required to induce
reduction in Akt/PKB activation in PTEN-deﬁcient cell lines, but
that at these concentrations also partially reduced activation of
Akt/PKB in the DLD1 cell line that harbours a PIK3CA mutation.
This would be consistent with our results from the present study
which demonstrate that binary combinations of A66 S, TGX-
221 and IC87114 induce varying degrees of partial inhibition of
activationofAkt/PKB,whereasthecombinationofallthreedrugs
induced maximal inhibition. This indicates that the three class-Ia
PI3K isoforms are functionally redundant to some extent and can
substitute each other in signalling to Akt/PKB in these PTEN-
null cells, as has been observed previously in other cell types
[31,51,52].
In the present study, activation of Akt/PKB was sensitive to
p110α inhibitors in H1047R cells but not in PTEN-null cell lines
and those harbouring E545K mutations, which is in agreement
with the studies of Torbett et al. [32] who used PIK-75. It
would be tempting to conclude that the sensitivity to p110α
inhibitors is a direct consequence of the presence of the H1047R
mutation, since this isoform has increased catalytic activity [13].
However, the PIK3CA mutants are not intrinsically sensitive
to A66 or PIK-75 (Table 1), and gene knockout studies have
shown that sensitivity of HCT-116 cells to p110α-selective PIK-
75 analogues is not changed by deletion of the H1047R allele
of PIK3CA [33]. Furthermore, the study by Torbett et al. [32]
showed that MCF10A cells and Hs578t cells were also sensitive
to PIK-75. The latter can be explained by the fact that this line
was subsequently found to have a mutation in PIK3R1 (Cosmic
database) and such mutations have been shown to be sensitive to
p110α inhibitors [34]. Although MCF10A cells have no reported
mutations in PI3K signalling pathways, a certain sub-population
of these cells has been reported to have high PI3K activity [53].
This is consistent with another study which observed PI3K is not
mutated inmedulloblastoma, but thatp110α isoverexpressed and
that such cells are very sensitive to PIK-75 [22]. Furthermore, we
have observed previously in other cells that the degree of PIK-75
sensitivity is proportional to the relative amount of the total PI3K
activity that is attributable to p110α [31]. Our results from the
present study also show that the cells with high overall class-Ia
PI3K and p110α protein levels are the ones that are sensitive to
p110α inhibitors. Therefore the increased catalytic activity of the
H1047mutantmaynotbesufﬁcientonitsowntoconfersensitivity
to p110α inhibitors, but rather it may be the total levels of p110α
(mutantorwild-type)inthecellsthatismostimportant.Inthisre-
garditisworthnotingthatevidencehasrecentlybeenpresentedto
indicatethatatleastpartoftheeffectoftheH1047Rmutantmight
be to stabilize p110α levels in the cell [53]. The relative levels of
class-IaPI3Kisoformsisalsolikelytobeimportantanditisinthis
regard it is noteworthy that MCF7 cells are partially responsive to
TGX-221, suggesting a dependence on p110β, and this cell line
istheonlyonewherewefoundhighp110β andlowp110α levels.
Further studies will be required to clarify these issues.
The reason for the difference in characteristics between the
H1047R and E545K cell lines is not clear. However, a number
of studies have indicated that these two main oncogenic forms
of p110α are likely to function differently in vitro and in vivo
[12,13,19–23]. In particular, the helical domain mutants appear
to signal independently of the p85 adapter subunit, and hence of
activation by receptor tyrosine kinases, but require Ras [54]. The
kinase domain mutants, on the other hand, require p85 but are
independent of Ras [54]. Again it will require further studies to
clarify this issue.
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The ﬁnding that A66 S is more effective at inducing growth
delay in the HCT-116 and SK-OV-3 xenograft models than the
pan-PI3K/mTOR inhibitor BEZ-235 [55] demonstrates that a
p110α-selectiveinhibitorcanbeeffectiveatslowingcellgrowthin
the absence of mTOR inhibition in certain cell types. In addition,
although A66 S did not induce tumour regression in xenograft
models, the ability to induce growth delay indicates p110α-
selective inhibitors have to ability to be effective as cytostatic
agents in some tumour types. Further studies will be required to
determine whether A66 might contribute to tumour regression as
part of a combination drug treatment strategy.
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Figure S2 Inhibition of kinases by A66
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Figure S3 Reprobes of blots in Figure 3 of the main paper with the total PKB antibody
Ly, LY294002.
Figure S4 A66 R enantiomer does not block signalling to PKB in cells with the PIK3CA H1047R mutation
Experiments were performed as in Figure 3 of the main paper, except that the R form of A66 was used. Ly, LY294002.
c   The Authors Journal compilation c   2011 Biochemical Society © 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.S. Jamieson and others
Figure S5 In vivo antitumour efﬁcacy and body weight change following treatment with A66 and BEZ-235 in the U87MG and HCT-116 tumour xenograft
models
(A) Average tumour volume and (B) body weight loss during QD×14 dosing with 100mg of A66/kg of body weight and 15mg of BEZ-235/kg of body weight in mice with U87MG tumours.
(C) Average tumour volume and (D) body weight loss during QD×7 dosing with 100mg of A66/kg of body weight and 10mg of BEZ-235/kg of body weight in mice with HCT-116 tumours. Bars
represent the means+ −S.E.M. for ﬁve to seven animals.
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